This website is an independent initiative of the historic and founding shareholders of OSE Immunotherapeutics. It is not the company's corporate website. Its purpose is to inform other shareholders and stakeholders about our positions and proposals in the context of the debate on strategy and governance.

Posts By :

Alexis Peyroles

Open Letter to the Shareholders of OSE Immunotherapeutics (OSE) Our vision as founding shareholders and former executives acting in concert
Chercheurs en laboratoire
Latest news

Open Letter to the Shareholders of OSE Immunotherapeutics (OSE) Our vision as founding shareholders and former executives acting in concert
Read all
1920 1024 OSE Immuno Together
The three founding shareholders deplore the headlong rush and misinformation of OSE’s current Board of Directors.
Loria Costantini Peyroles
Latest news

The three founding shareholders deplore the headlong rush and misinformation of OSE’s current Board of Directors.
Read all
1536 1024 OSE Immuno Together
General Meeting of September 30: The three founding shareholders call for a complete renewal of the Board of Director
Latest news

General Meeting of September 30: The three founding shareholders call for a complete renewal of the Board of Director
Read all
1536 1024 OSE Immuno Together
Reaction of the Three Founding and Concerted Shareholdersto the Latest Announcements from OSE Immunotherapeutics
Communique de presse
Latest news

Reaction of the Three Founding and Concerted Shareholdersto the Latest Announcements from OSE Immunotherapeutics
Read all
1920 1281 OSE Immuno Together
Shareholder note dated June 20, 2025, informing about our action to contest the extension until September 30, 2025, for holding the General Meeting.
Latest news

Shareholder note dated June 20, 2025, informing about our action to contest the extension until September 30, 2025, for holding the General Meeting.
Read all
1536 1024 OSE Immuno Together
Letter to shareholders ahead of OSE Immunotherapeutics SA’s June 25, 2025 Combined General Meeting, setting out the reasons for our 10 draft resolutions.
Latest news

Letter to shareholders ahead of OSE Immunotherapeutics SA’s June 25, 2025 Combined General Meeting, setting out the reasons for our 10 draft resolutions.
Read all
2560 904 OSE Immuno Together
Close